Forte Biosciences (FBRX)
(Real Time Quote from BATS)
$10.37 USD
-0.21 (-1.99%)
Updated Aug 7, 2025 03:32 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FBRX 10.37 -0.21(-1.99%)
Will FBRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FBRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FBRX
All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why
FBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock?
Other News for FBRX
Sixteen new option listings on July 23rd
FEDERATED HERMES, INC. Acquires 1,072,233 Shares in Forte Biosciences Inc
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Forte Biosciences Announces Public Offering of Shares